SunTrust Banks, Inc. restated their buy rating on shares of Amedisys Inc (NASDAQ:AMED) in a report issued on Monday, October 9th. They currently have a $60.00 price target on the health services provider’s stock.
A number of other equities analysts have also weighed in on the company. Robert W. Baird reiterated a hold rating and set a $50.00 price objective on shares of Amedisys in a research note on Wednesday, October 4th. Oppenheimer Holdings, Inc. restated a buy rating and set a $60.00 target price on shares of Amedisys in a research report on Friday, September 15th. Bank of America Corporation initiated coverage on Amedisys in a research report on Monday, August 21st. They set a neutral rating and a $55.00 target price on the stock. BidaskClub upgraded Amedisys from a sell rating to a hold rating in a research report on Friday, August 11th. Finally, Mizuho cut Amedisys from a buy rating to a neutral rating and set a $50.00 target price on the stock. in a research report on Wednesday, July 26th. Seven research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $56.20.
Shares of Amedisys (NASDAQ AMED) opened at 50.27 on Monday. Amedisys has a 12-month low of $34.58 and a 12-month high of $65.91. The company has a market capitalization of $1.70 billion, a PE ratio of 42.97 and a beta of 0.87. The stock’s 50 day moving average price is $51.65 and its 200 day moving average price is $55.05.
Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.12. The business had revenue of $378.80 million during the quarter, compared to analyst estimates of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The company’s revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the business posted $0.42 EPS. On average, equities research analysts forecast that Amedisys will post $2.21 earnings per share for the current year.
In other Amedisys news, Director Bruce D. Perkins bought 2,000 shares of the firm’s stock in a transaction on Thursday, August 3rd. The shares were acquired at an average cost of $46.60 per share, with a total value of $93,200.00. Following the purchase, the director now directly owns 15,825 shares of the company’s stock, valued at approximately $737,445. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, insider David B. Pearce sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the completion of the transaction, the insider now directly owns 10,488 shares in the company, valued at $524,400. The disclosure for this sale can be found here. Company insiders own 2.00% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Riverhead Capital Management LLC raised its position in shares of Amedisys by 75.5% during the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock valued at $121,000 after buying an additional 831 shares during the period. Federated Investors Inc. PA raised its position in shares of Amedisys by 2.3% during the 2nd quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock valued at $122,000 after buying an additional 44 shares during the period. Ameritas Investment Partners Inc. purchased a new stake in shares of Amedisys during the 1st quarter valued at approximately $123,000. Quantitative Systematic Strategies LLC purchased a new stake in shares of Amedisys during the 3rd quarter valued at approximately $205,000. Finally, CIBC Asset Management Inc purchased a new stake in shares of Amedisys during the 2nd quarter valued at approximately $230,000. 96.55% of the stock is currently owned by hedge funds and other institutional investors.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with our FREE daily email newsletter.